![Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e3c72f61-a492-4da1-91d5-e001df9a3e34/gr1_lrg.gif)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial - ScienceDirect Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1526820920302585-fx4.jpg)
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial - ScienceDirect
![Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers - ScienceDirect Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1535610819305835-fx1.jpg)
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers - ScienceDirect
![Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/2016-09/medicin15.jpg?VersionId=3CogD4YQi.2znGgf99ntdmU4af1X0DuG)
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
![Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects](https://www.researchgate.net/publication/335752107/figure/fig2/AS:960057118318608@1605906862529/Box-plots-of-neratinib-exposure-parameters-where-the-mean-is-represented-by-diamond_Q320.jpg)
Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects
![Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c94df385-dbfb-490e-b30e-4c8e5774e824/gr1.gif)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer - Clinical Breast Cancer Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer - Clinical Breast Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/427061e3-2a9c-44c6-8ce3-b29eca8e0075/gr1_lrg.jpg)
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer - Clinical Breast Cancer
![Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2017/6/7/24288543-14968418721801043_origin.png)
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
![Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur](http://www.brimr.org/PKI/Neratinib.jpg)
Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur
![Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire](https://mms.businesswire.com/media/20190401005264/en/396178/22/puma_logo_JPEG.jpg)
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
![PDF) How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer PDF) How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer](https://i1.rgstatic.net/publication/352005571_How_to_Optimise_Extended_Adjuvant_Treatment_with_Neratinib_for_Patients_with_Early_HER2_Breast_Cancer/links/60b519a6a6fdcc476bda6562/largepreview.png)